Watch for the pricing and share count details in the prospectus supplement; typical discounts for clinical-stage biotech follow-on offerings are 4-6%. Near-term dilution and potential overhang from the greenshoe may pressure RLAY. The historical calibration shows mixed outcomes for score-8 filings on this ticker, but the cross-filing amplifier signals that this activist+offering combo tends to move significantly — expect elevated volatility.
Price Chart
Executive Summary
Relay Therapeutics announced a $175 million underwritten public offering of common stock, with an additional 15% option for underwriters. Proceeds are undisclosed but will support clinical development, including the Phase 3 trial of zovegalisib in HR+/HER2- metastatic breast cancer and other pipeline programs. The dilutive offering comes as a clinical-stage biotech with no approved products, putting pressure on the stock near-term due to dilution.
Key Financial Metrics
Key Facts
- Relay Therapeutics commenced an underwritten public offering of $175 million shares of common stock.
- Underwriters have a 30-day option to purchase up to an additional 15% of shares.
- All shares are offered by the company; Jefferies, TD Cowen, Goldman Sachs, Guggenheim Securities are joint book-runners, Raymond James is lead manager.
- The offering is under an automatically effective shelf registration statement (S-3ASR) filed August 6, 2024.
- Zovegalisib is the lead asset, in Phase 3 for HR+/HER2- metastatic breast cancer and also in genetic disease indications.
- The company is clinical-stage with no approved products — the offering is dilutive with no near-term revenue to offset it.
Financial Impact
A $175 million offering (plus up to ~$26.25M from the greenshoe) against a $2.3B market cap implies ~7.6% base dilution, rising to ~8.7% if the full over-allotment is exercised. Proceeds will fund pipeline R&D with no offsetting revenue.
Risk Factors
- Dilution of ~7.6-8.7% of outstanding shares reduces EPS and ownership percentage.
- Clinical-stage company with no approved products — burn rate is high and offering signals need for additional capital beyond existing runway.
- Market conditions could cause the offering to be priced at a larger discount or canceled.
- Zovegalisib Phase 3 readout is still pending; negative data would compound dilution effects.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3297938 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $18.66 $18.84 | ▲ +0.96% | ▲ +1.62% | $18.96 (+1.61%) |
Aug 28, 2026 5w ago | Insider Cluster | $18.77 $19.04 | ▼ −1.44% | ▼ −1.33% | $18.96 (−1.01%) |
Aug 18, 2026 6w ago | Insider Cluster | $20.61 $20.57 | ▲ +0.19% | ▼ −0.01% | $18.96 (+8.01%) |
Jul 8, 2026 12w ago | Insider Cluster | $19.63 $19.08 | ▼ −2.80% | ▼ −3.66% | $18.96 (−3.41%) |
Jun 22, 2026 14w ago | 144 | $17.44 $19.74 | ▲ +13.19% | ▲ +12.18% | $18.96 (+8.72%) |
Jun 12, 2026 16w ago | Institutional Cluster | $14.81 $15.88 | ▲ +7.22% | ▲ +6.55% | $18.96 (+28.02%) |
May 21, 2026 19w ago | 8-K | $13.53 $14.26 | ▼ −5.40% | ▼ −3.74% | $18.96 (−40.13%) |
May 21, 2026 19w ago | Press Release | $13.66 $14.05 | ▼ −2.86% | ▼ −1.01% | $18.96 (−38.80%) |
May 19, 2026 19w ago | 424B5 | $13.02 $13.90 | ▼ −6.76% | ▼ −4.96% | $18.96 (−45.62%) |
May 19, 2026 19w ago | Press Release | $13.02 $14.43 | ▼ −10.83% | ▼ −9.59% | $18.96 (−45.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access